p53 expression in colorectal carcinomas and its correlation with clinicopathological parameters

Mardi, Kavita; Sharma, Man Mohan; Bhardwaj, Meena; Mv, Rao

doi:10.4103/ccij.ccij_5_17

Cited by 7 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings of the research determined that the optimal cut‐off value of the P53 index was 67%. In the present study, patients with a higher P53 index were more likely to be accompanied by aggressive clinicopathological parameters, which were also confirmed in previous relevant studies 9,14‐16 . It suggested that the over expression of the P53 index played an important role in the malignant transformation and differentiation of endometrial cells, which indicated that the optimal cut‐off value had potential value for predicting the recurrence of endometrial cancer.…”

Section: Discussionsupporting

confidence: 89%

The optimal cut‐off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer

Jia

Jiang

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

Objective To explore the optimal cut‐off value of immunohistochemical parameter P53 for predicting the recurrence of Stage I–III endometrial cancer. Methods A total of 473 patients who were treated between October 2013 and May 2018 were retrospectively studied. Receiver operating characteristic (ROC) curves and the Youden index were used to calculate the optimal cut‐off value of P53. Cox regression analysis was used to detect the association between the threshold of P53 and recurrence of endometrial cancer. Recurrence‐free survival (RFS) and overall survival (OS) were exhibited by Kaplan–Meier curve. Results The study showed that 67% was the optimal cut‐off value of P53 to predict the recurrence of endometrial cancer. P53 above 67% was an independent predictor for relapse of endometrial cancer (p < 0.001). The 3‐year RFS was 89.7% in the low‐value group and 66.6% in the high‐value group (p < 0.001), while the 3‐year OS was 93.9% and 76.4%, respectively (p < 0.001). Furthermore, the 3‐year RFS of patients who did not receive adjuvant chemotherapy or radiotherapy was 95.7% and 78.2% between the two groups (p < 0.001). Conclusion The optimal cut‐off value of immunohistochemical parameter P53 for predicting recurrence was confirmed as 67% and a P53 index above 67% was an independent prognostic factor.

show abstract

Section: Discussionsupporting

confidence: 89%

The optimal cut‐off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer

Jia

Jiang

et al. 2020

Intl J Gynecology & Obste

View full text Add to dashboard Cite

show abstract

“…In our study mean age of the patients was 56.63 +/-14.03 which was in concordance with the study by Kavitha Mardi [7] and Hunaldo Lima de Menzes.…”

Section: Discussionsupporting

confidence: 92%

“…[9] Majority of the tumors were located in the left side of the colon -18 (60%) and 12 (40%) were located in the right side of the colon, which were in concordance with the studies by Azza Hegazy , [12] Kavitha Mardi , [7] Guru Raja Prasad.…”

Section: Discussionsupporting

confidence: 83%

See 1 more Smart Citation

Immunohistochemical Study of p53 Expression in Colorectal Adenocarcinomas and its Clinicopathological Correlation

Chithrra

John

Ganapathy

et al. 2018

APALM

View full text Add to dashboard Cite

Background: Colorectal carcinoma is the fourth most frequent cancer in men and the third in women worldwide. The identification of molecular markers that have a prognostic significance in colorectal carcinoma may have an impact on its treatment. This study aims to identify and evaluate the immunohistochemical expression of p53 in colorectal adenocarcinomas and to correlate its expression with various clinicopathological parameters. Methods:The present study was an observational study done in 30 surgical resection specimens received in the Department of Pathology, SRM Medical College and Research Centre, Kattankulathur, Tamil Nadu from June 2015-June 2017. Clinical history and clinicopathological parameters were obtained ,histomorphological and immunohistochemical evaluation was done and the results were correlated with clinicopathological variables. The IHC panel we used was mouse monoclonal p53 antibody (PathnSitu).Result: In our study, p53 overexpression was noted in 70% cases of colorectal adenocarcinomas. p53 overexpression was noted more in conventional adenocarcinomas (85.7%), more in left sided colonic carcinomas (71.4%), in advanced pT stage (57.1% in pT3) and also in cases with lymph node metastasis (57.1%). No statistically significant correlation of p53 with other clinicopathological variables such as age, gender, nature of specimen, tumor site, size, histological type, grade, tumor perforation, bowel wall invasion and perineural invasion were noted. Conclusion:Our study supports that p53 overexpression is an indicator of poor prognosis and may prove as an useful marker in identifying high risk patients who may benefit from adjuvant therapy in the early stage of disease.

show abstract

“…Most of the primary oral and para oral NHLs is DLBCL histological type [1] [2]. DLBCL is a heterogeneous disease that shows various outcomes [3]. It is a neoplasm of large transformed B cells with a diffuse growth pattern.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of BCL2 Protein in Diffuse Large Cell Lymphoma of Head and Neck; Relation to Response to Chemotherapy

Elhendawy¹,

Ibrahiem²,

Elmahdi³

et al. 2020

OJPathology

View full text Add to dashboard Cite

Diffuse large B cell lymphoma (DLBCL) is a heterogeneous disease that displays a highly variable clinical outcome. It is a neoplasm of large transformed B cells with a diffuse growth pattern. DLBCL is the most common type of non-Hodgkin's lymphoma (NHL) (31% of all cases). Approximately half of patients with DLBCL are cured with current chemotherapy regimens. The purpose of this study was to evaluate BCl2 expression in 45 patients diagnosed with DLBCL of head and neck region and correlate the level of its immunohistochemical expression with different clinicopathological variables with emphasis upon patients' age, gender, nodal or extra-nodal location of lymphoma, patients' response to chemotherapy, progression-free survival (PFS) and overall survival (OS). A retrospective analysis of 45 patients diagnosed to have DLBCL. A cut off value of ≥ 50% protein expression denoted BCL2 positivity. Out of 45 cases, 36 cases (80%) revealed BCL2 positive expression and 9 cases (20%) were BCL2 negative. We found statistically significant differences in BCL2 expression regarding different patients' responses to chemotherapy, patients' OS and PFS (p ≤ 0.05). No statistically significant differences in BCL2 expression regarding the patients' Ann Arbor clinical stage, age group and tumor site (nodal or extra-nodal, p > 0.05) using the Chi-square test. BCL2 expression was analyzed in relation to 5 years OS and PFS using Kaplan Meier curves and Log Rank test for survival analysis. Cases that demonstrated BCL2 positivity revealed shortened OS and PFS with highly statistically significant differences among the studied variables (p = 0.000). We also found that patients who respond well to the chemotherapeutic regimen had negative BCL2 expression, the differences were statistically signifi-cant (p = 0.015). In conclusion, BCL2 expression could be considered a predictor for patients' chemotherapeutic response, OS and PFS.

show abstract

p53 expression in colorectal carcinomas and its correlation with clinicopathological parameters

Cited by 7 publications

References 0 publications

The optimal cut‐off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer

The optimal cut‐off value of immunohistochemical parameter P53 for predicting recurrence of endometrial cancer

Immunohistochemical Study of p53 Expression in Colorectal Adenocarcinomas and its Clinicopathological Correlation

Prognostic Significance of BCL2 Protein in Diffuse Large Cell Lymphoma of Head and Neck; Relation to Response to Chemotherapy

Contact Info

Product

Resources

About